Government-Owned Inventions; Availability for Licensing, 24321-24322 [2018-11256]

Download as PDF Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings amozie on DSK3GDR082PROD with NOTICES1 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Next Generation Multipurpose Prevention Technologies (NGM) (R61/R33 Clinical Trial Optional). Date: June 12, 2018. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Audrey O. Lau, Ph.D., MPH, Scientific Review Officer AIDS REVIEW BRANCH SRP, RM 3E70, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9834, Rockville, MD 20852–9834, 240–669–2081, audrey.lau@nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Partnerships for Countermeasures against Select Pathogens (R01). Date: June 28–29, 2018. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Amir E. Zeituni, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities NIAID/NIH/DHHS, 5601 Fishers Lane, MSC– 9834, Rockville, MD 20852, 301–496–2550, amir.zeituni@nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Partnerships for Countermeasures against Select Pathogens (R01). Date: July 10–11, 2018. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). VerDate Sep<11>2014 18:28 May 24, 2018 Jkt 241001 Contact Person: Amir E. Zeituni, Ph.D., Scientific Review Officer Scientific Review Program Division of Extramural Activities NIAID/NIH/DHHS, 5601 Fishers Lane, MSC– 9834, Rockville, MD 20852, 301–496–2550, amir.zeituni@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: May 21, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–11215 Filed 5–24–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing. FOR FURTHER INFORMATION CONTACT: Dr. Amy Petrik, 240–627–3721; amy.petrik@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Antibodies and Methods for the Diagnosis and Treatment of EpsteinBarr Virus Infection Description of Technology According to the World Health Organization, over 90% of the worldwide population is infected with Epstein-Barr virus by adulthood. In most cases, the disease accompanying initial infection is subclinical though some individuals who are infected as adolescents or adults do experience infectious mononucleosis. However, once infected, individuals carry latent EBV for their remaining lifespan. In such individuals, immune suppression PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 24321 can result in reactivation of the EBV and consequently, EBV-associated lymphoproliferative disease. Currently, there is no prophylactic to prevent primary EBV infection and additional therapeutics would be useful to treat EBV-associated B-cell driven lymphoproliferative disease. Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10–100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1). The antibodies target epitopes on either the gp350 surface glycoprotein of EBV or the gH/gL heterodimer. In vitro experiments have demonstrated that the antibodies effectively inhibit EBV infection of B cells and epithelial cells as well as cell-to-cell fusion of cells expressing the viral proteins gH/ gL. Potential Commercial Applications • Treatment of individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases. • Prevention of primary EBV infection in individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases. Competitive Advantages • No EBV therapeutics or prophylactics currently exist. Development Stage • In vitro Inventors: Masaru Kanekiyo (NIAID), W. Gordon Joyce (WRAIR), Wei Bu (NIAID), Jeffrey Cohen (NIAID). Publications: N/A. Intellectual Property: HHS Reference Number E–001–2017 includes U.S. Provisional Patent Application No. 62/ 490,023 filed April 25, 2017 (Pending); PCT Application No. PCT/US2018/ 29463 filed April 25, 2018. HHS Reference Number E–079–2018 includes U.S. Provisional Patent Application No. 62/665,977 filed May 2, 2018. Related Intellectual Property: HHS Reference Number E–001–2017; E–079– 2018. Licensing Contact: Dr. Amy Petrik, 240–627–3721; amy.petrik@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to E:\FR\FM\25MYN1.SGM 25MYN1 24322 Federal Register / Vol. 83, No. 102 / Friday, May 25, 2018 / Notices further develop, evaluate or commercialize Epstein-Barr monoclonal antibody technologies. For collaboration opportunities, please contact Dr. Amy Petrik, 240–627–3721; amy.petrik@ nih.gov. Dated: May 10, 2018. Suzanne M. Frisbie Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–11256 Filed 5–24–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Amy Petrik, Ph.D., 240–627–3721; amy.petrik@nih.gov. Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Middle East Respiratory Syndrome Coronavirus Antibodies amozie on DSK3GDR082PROD with NOTICES1 Description of Technology Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ∼35% mortality. Currently there are no prophylactic measures or effective therapies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing VerDate Sep<11>2014 18:28 May 24, 2018 Jkt 241001 monoclonal antibodies (nMAbs) against the MERS-CoV. This invention describes antibodies that target the Spike (S) glycoprotein on the coronavirus surface, which mediates viral entry into host cells. These novel antibodies target different regions of the S protein, and when administered in combination, reduce the possibility of viral escape. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways and severe disease in challenge studies with mice. In addition, these nMAbs have potential application for use in assays for detecting MERS-CoV S protein in infected patients or animals. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications Monoclonal antibodies developed against multiple regions of the coronavirus spike protein have potential application in the prevention and treatment of MERS-CoV. There is also potential application for their use as a diagnostic tool of infection. Competitive Advantages • In vitro models, the combinations of antibodies have been demonstrated to be effective in reducing viral escape. • In vivo data in animal models demonstrated a potent ability to control infection. • Applicable in diagnostic assays. Development Stage • In vivo data available (animal) Inventors: Barney Graham (NIAID), Wing-Pui Kong (NIAID), Kayvon Modjarrad (NIAID), Lingshu Wang (NIAID), Wei Shi (NIAID), Michael Gordon Joyce (NIAID), Masaru Kanekiyo (NIAID), John Mascola (NIAID). Intellectual Property: HHS Reference No. E–239–2014, U.S. Provisional Patent Application Number 62/120,353 filed February 25, 2015, PCT Patent Application PCT/US2016/019395 filed February 24, 2016, Europe Patent Application Number 16711059.2 filed February 24, 2016, South Korea Patent Application Number 10–2017–7027105 filed September 25, 2017, Saudi Arabia Patent Application Number 5173382168 filed August 21, 2017, and U.S. Patent Application Number 15/553,466 filed August 24, 2017. Licensing Contact: Amy Petrik Ph.D., 240–627–3721; amy.petrik@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize MERS-CoV monoclonal antibodies. For collaboration opportunities, please contact Amy Petrik, Ph.D., 240–627–3721; amy.petrik@nih.gov. Dated: May 14, 2018. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–11255 Filed 5–24–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Advisory Eye Council, June 14, 2018, 08:30 a.m. to June 14, 2018, 05:00 p.m., NIH, National Eye Institute, 5635 Fishers Lane, Terrace Level Conference Rooms, Rockville, MD 20852 which was published in the Federal Register on May 04, 2018, 83 FR 19791. This meeting is being amended to change the Open and Close times. The Closed portion is now from 8:30 a.m. to 10:30 a.m. The Open portion is now from 10:45 a.m. to 3:00 p.m. The meeting is partially Closed to the public. Dated: May 21, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–11211 Filed 5–24–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, E:\FR\FM\25MYN1.SGM 25MYN1

Agencies

[Federal Register Volume 83, Number 102 (Friday, May 25, 2018)]
[Notices]
[Pages 24321-24322]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-11256]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Amy Petrik, 240-627-3721; 
[email protected]. Licensing information and copies of the U.S. patent 
application listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr 
Virus Infection

Description of Technology

    According to the World Health Organization, over 90% of the 
worldwide population is infected with Epstein-Barr virus by adulthood. 
In most cases, the disease accompanying initial infection is 
subclinical though some individuals who are infected as adolescents or 
adults do experience infectious mononucleosis. However, once infected, 
individuals carry latent EBV for their remaining lifespan. In such 
individuals, immune suppression can result in reactivation of the EBV 
and consequently, EBV-associated lymphoproliferative disease. 
Currently, there is no prophylactic to prevent primary EBV infection 
and additional therapeutics would be useful to treat EBV-associated B-
cell driven lymphoproliferative disease.
    Scientists at the NIAID are developing neutralizing antibodies, 
originally isolated from humans or non-human primates, that could be 
useful in preventing primary infection or reactivation of EBV in 
immunocompromised individuals. These antibodies are 10-100 times more 
potent than the most potent EBV neutralizing antibody identified to 
date (72A1). The antibodies target epitopes on either the gp350 surface 
glycoprotein of EBV or the gH/gL heterodimer. In vitro experiments have 
demonstrated that the antibodies effectively inhibit EBV infection of B 
cells and epithelial cells as well as cell-to-cell fusion of cells 
expressing the viral proteins gH/gL.

Potential Commercial Applications

     Treatment of individuals with compromised immune systems 
to prevent EBV-associated lymphoproliferative diseases.
     Prevention of primary EBV infection in individuals with 
compromised immune systems to prevent EBV-associated 
lymphoproliferative diseases.

Competitive Advantages

     No EBV therapeutics or prophylactics currently exist.

Development Stage

     In vitro
    Inventors: Masaru Kanekiyo (NIAID), W. Gordon Joyce (WRAIR), Wei Bu 
(NIAID), Jeffrey Cohen (NIAID).
    Publications: N/A.
    Intellectual Property: HHS Reference Number E-001-2017 includes 
U.S. Provisional Patent Application No. 62/490,023 filed April 25, 2017 
(Pending); PCT Application No. PCT/US2018/29463 filed April 25, 2018.
    HHS Reference Number E-079-2018 includes U.S. Provisional Patent 
Application No. 62/665,977 filed May 2, 2018.
    Related Intellectual Property: HHS Reference Number E-001-2017; E-
079-2018.
    Licensing Contact: Dr. Amy Petrik, 240-627-3721; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to

[[Page 24322]]

further develop, evaluate or commercialize Epstein-Barr monoclonal 
antibody technologies. For collaboration opportunities, please contact 
Dr. Amy Petrik, 240-627-3721; [email protected].

    Dated: May 10, 2018.
Suzanne M. Frisbie
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-11256 Filed 5-24-18; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.